Jesus Alonso Gandara Mireles | Pharmacology, Toxicology and Pharmaceutical Science | Young Scientist Award

Posted on by ScienceFather

Dr. Jesus Alonso Gandara Mireles | Pharmacology, Toxicology and Pharmaceutical Science | Young Scientist Award

Researcher,  National Polytechnic Institute,  Mexico.

Jesús Alonso Gándara Mireles is an exemplary candidate for the Research for Young Scientist Award, with extensive qualifications in biotechnology. He holds a Bachelor’s degree and multiple master’s degrees, culminating in a PhD focused on pharmacokinetics and pharmacogenetics in oncology. Currently completing a Postdoctoral Fellowship at the National Polytechnic Institute, Jesús conducts research aimed at optimizing chemotherapy for pediatric cancer patients. His experience includes prestigious internships at the University at Buffalo and the University of San Diego, enhancing his expertise. As a member of key professional organizations, he demonstrates a strong commitment to advancing personalized medicine and improving patient outcomes.

Publication Profile :

Scopus

Educational Background :

Jesús’s educational achievements are impressive and relevant to his research interests. He holds a Bachelor’s degree in Biotechnology with a biomedical focus, followed by a Master’s in Molecular and Cellular Biology, a Master’s in Human Genetics, and a Master’s in Clinical Pharmacokinetics. His PhD, centered on pharmacokinetics and pharmacogenetics in oncology, underscores his specialized knowledge in this vital area of research. This rigorous academic training has equipped him with the necessary skills to tackle complex scientific problems in the field of cancer treatment.

Professional Experiences :

Jesús Alonso Gándara Mireles has accumulated extensive professional experience in biotechnology and clinical research, particularly in the fields of pharmacogenetics and pharmacokinetics. Currently, he is completing a Postdoctoral Fellowship at the National Polytechnic Institute (IPN), focusing on the pharmacokinetics of oncology agents in pediatric patients. His previous internships include significant roles in Clinical Pharmacokinetics at the National Institute of Pediatrics and Pediatric Cancer Pharmacology at the University at Buffalo. He also engaged in research on Pediatric Cancer Genetics at the University of San Diego. His work aims to optimize treatment strategies and reduce chemotherapy-induced adverse effects in childhood cancer.

Research Contribution  :

Throughout his career, Jesús has gained valuable research experience through multiple internships. His exposure to pharmacokinetics and pharmacogenetics at prestigious institutions, including the University at Buffalo and the University of San Diego, highlights his capability to engage with leading experts and contribute to groundbreaking research. His current work focuses on optimizing chemotherapy for children by reducing adverse effects through personalized medicine, emphasizing his innovative approach to healthcare challenges.

Awards And Achievements :

Jesús Alonso Gándara Mireles has earned notable recogn ition throughout his academic and research career. As a member of the National System of Researchers (CONACYT) at Level 1, he has demonstrated his commitment to advancing scientific knowledge. His research contributions have been acknowledged through prestigious internships, including those at the National Institute of Pediatrics and the University at Buffalo. Additionally, Jesús is an active member of the International Society of Pediatric Oncology (SIOP) and the Latin American Society of Pharmacogenomics and Personalized Medicine (SOLFAGEM). These affiliations reflect his dedication to pediatric oncology and personalized medicine, underscoring his impactful contributions to the field.

Conclusion : 

Jesús Alonso Gándara Mireles is an outstanding candidate for the Research for Young Scientist Award. His impressive educational background, significant research experience, and active participation in professional networks make him a valuable contributor to the field of biotechnology and pediatric oncology. His work has the potential to greatly improve treatment outcomes for children with cancer, demonstrating his commitment to advancing scientific knowledge and enhancing patient care. Therefore, I strongly endorse his nomination for this esteemed award.

Publication Top Notes :

  • “Influence of Age, Gender and Body Mass Index on Intravenous Pharmacokinetics of Buprenorphine in Children Undergoing Orthopedic Surgery” (2024) – 🏥
  • “Population pharmacokinetics and pharmacodynamics of L-asparaginase and its impact on the development of pancreatitis and hypersensitivity reactions in children with leukemia under treatment” (2024) – 🧬
  • “Nutritional Status as a Risk Factor for Doxorubicin Cardiotoxicity in Mexican Children with Acute Lymphoblastic Leukemia” (2024) – 🍽️
  • “Impact of single-nucleotide variants and nutritional status on population pharmacokinetics of Doxorubicin, and its effect on cardiotoxicity in children with leukemia” (2023) – ⚗️ Cited by: 3
  • “Association of genetic polymorphisms NCF4 rs1883112, CBR3 rs1056892, and ABCC1 rs3743527 with the cardiotoxic effects of doxorubicin in children with acute lymphoblastic leukemia” (2021) – 🧬 Cited by: 8
  • “Genotype Analysis of ABCC1, NCF4 and CBR3 Polymorphism and the Association With Childhood Acute Lymphoblastic Leukemia in Mexican Childhood Population” (2021) – 🔬 Cited by: 3

Shubham Sharma | Pharmacology | Best Researcher Award

Posted on by ScienceFather

Shubham Sharma | Pharmacology | Best Researcher Award

Dr Shubham Sharma, Pfizer, United States

Dr. Shubham Sharma is a leading computational modeler with 8+ years of expertise in theoretical materials science, physics, and chemistry. Holding a Ph.D. in Chemical & Environmental Engineering from Brown University (2021), he specializes in atomistic modeling and solid-form design, notably working at Pfizer where he leads drug de-risking efforts. His research in catalysis, electrochemistry, and crystal structure predictions has earned him over 10 Pfizer Bravo awards. Dr. Sharma’s groundbreaking work is recognized globally, including invited talks at major conferences, advancing both pharmaceutical and renewable energy applications. 💻🔬💊⚡

Publication Profile

Google Scholar

Education

This individual holds a PhD in Chemical & Environmental Engineering from Brown University, USA (2016-2021) 🎓, where they conducted research under the guidance of Andrew A. Peterson 🧑‍🔬. Their academic journey began with a Bachelor of Technology (B. Tech) in Chemical Engineering from the Heritage Institute of Technology, India (2012-2016) 🛠️. With a strong foundation in chemical engineering, they have pursued advanced studies focusing on environmental solutions and sustainability 🌍. Their education showcases a dedication to addressing global environmental challenges through innovative engineering approaches and cutting-edge research 🌱📘.

Work Experience

Currently serving as a Senior Scientist in Computational Materials Science at Pfizer Inc. (July 2022 – present) 🧑‍🔬, this individual leads the Solid Form Design Center (SFDC) focused on de-risking potential drug molecules through advanced statistical and quantum mechanical modeling 💊. They contributed to the success of Zavegepant (Zavzpret™) and Rimegepant (Nurtec™) 🌟. As a core member of the Crystal Structure Prediction team, they specialize in electronic structure theory, density functional theory, and atomistic modeling 🧬. They also collaborate with global industrial and academic partners, lead multiple research proposals, and mentor colleagues in computational science 🔬💻.

Selected conference presentations

Sharma has delivered numerous invited talks and presentations globally 🌍. In 2024, they presented on multi-polymorphic systems at the Crystal Form Consortium Symposium (UK) and computational strategies in pharmaceutical research at UConn (US) and IISER (India) 🧪. Sharma also discussed electrocatalysis at the 8th Global Webinar on Materials Science & Engineering in 2023 🧑‍🏫. Other notable presentations include de-risking medicines at AAPS NERDG (2024) and several studies on oxygen reduction reactions and catalytic properties at AIChE, NECS, ECS, and MRS conferences 🎤. Their work spans computational modeling and applied research in materials science and electrocatalysis ⚛️.

Research Focus

The research focus of Sharma spans electrochemistry, catalysis, and materials science. Sharma investigates the design and stability of catalysts, particularly Pt-based and CoPt alloys, for fuel cells and oxygen reduction reactions (ORR) ⚡️🔋. His work includes dynamic stability, reaction barriers, and potential-controlled reactions, using advanced techniques like density functional theory (DFT) and experimental-theoretical integration. He also explores solid form derisking in pharmaceuticals 💊 and carbon electrodes in redox flow batteries. Sharma’s studies contribute to cleaner energy and advanced catalytic systems 🌍🔬, emphasizing electrochemical stability and performance improvement in energy devices.

 

Publication Top Notes

Hard-magnet L10-CoPt nanoparticles advance fuel cell catalysis

Anisotropic Strain Tuning of L10 Ternary Nanoparticles for Oxygen Reduction

Face-centered tetragonal (FCT) Fe and Co alloys of Pt as catalysts for the oxygen reduction reaction (ORR): A DFT study

Ordered CoPt oxygen reduction catalyst with high performance and durability

Metal dissolution from first principles: Potential-dependent kinetics and charge transfer

Assessment of carbon monoxide exposure in roadside food-vending shanties using coal cookstoves in Kolkata, India

Dynamic stability of Pt-based alloys for fuel-cell catalysts calculated from atomistics

Conclusion

Dr. Shubham Sharma’s innovative research in computational modeling and materials science, alongside his leadership in both academic and industrial collaborations, makes him an exceptional candidate for the Best Researcher Award. His contributions have not only advanced pharmaceutical drug design but also impacted renewable energy research, marking him as a distinguished leader in his field.